ClinicalTrials.gg
RecruitingNCT05731856Updated Feb 18, 2026

Impact of Heart Rate Variability Modulation on Stress Management Among Physicians

An interventional study of Apollo Wearable in Burnout, Professional, sponsored by Michelle Thompson. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-18.

Sponsored by Michelle Thompson · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Jan 2024; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 97 studies in Burnout, Professional with a site in United States — 11 open to participants now, 16 under way, none of them phase 3. Burnout, Professional · United States.

Planned enrollment
60th of 90
50 · median 77
Started
2024
with 5 others
No phase
88 of 97
9 open now
Primary completion
2027-11
later than 11 of 15 live
Registered
74th of 97
by date

Among the 97 studies in Burnout, Professional with a site in United States, this one is the 60th largest by planned enrollment of the 90 interventional ones that give a count, is one of 6 that started in 2024, is one of 88 with no phase, reaches primary completion later than 11 of the 15 other live ones, and was the 74th registered.

Burnout, Professional

218 studies on the registry are indexed under Burnout, Professional; 35 are open to participants now.

Browse Burnout, Professional studies →

Open to participants now

11 of the 97 studies in Burnout, Professional with a site in United States are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 14 Burnout, Professional studies recruiting now, 9 (64%) set no upper age limit and 5 (36%) stop at 75 or younger; 1 takes children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 97 studies in Burnout, Professional with a site in United States, or all of them as a file.
02

Study summary

The purpose of this research is to examine a wearable device called Apollo that emits gentle vibrations found to benefit mood, energy, and focus. We want to understand how it affects burnout in physicians.

Read the detailed description

This study will be conducted by using a Tuned Vibroacoustic Stimulation (TVS) device(the commercially available TVS device known as the Apollo wearable), that has been shown in clinical studies at University of Pittsburgh to improve heart rate variability and recovery under stress. The Apollo wearable generates low volume sound waves that feel like a soothing touch to the skin. This study will assess whether slight modulation of heart rate variability (HRV) will result in a reduction in stress, improved recovery, and recovery in and around the hospital. Physicians will wear the Apollo device for heart rate variability modulation and complete questionnaires before and after use of the Apollo device for comparison of outcomes.

03

Conditions studied

  • Burnout, Professional

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • UPMC attending physicians and residents. The participants must have either IOS or Android phones.

Exclusion criteria

Exclusion Criteria:

  • Unwillingness or inability to participate in the study
  • Currently own an Apollo device
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Apollo Intervention Arm

    Eligible UPMC Physicians and Residents who consent to be part of this study will use an Apollo Device TVS (10-200 Hz) attached to the subject's wrist or ankle via a commercially available wearable vibration technology that can deliver TVS (Transcutaneous Vibratory Stimulation). The intensity will be targeted for the sensory threshold (the level at which the vibration is just noticeable), as this is where the TVS seems most effective from prior studies. Similar vibratory stimuli have been demonstrated to be safe in the literature. The intensity of the vibration will be adjusted to the subjects' comfort and can be controlled by the subject at any time.

    Device: Apollo Wearable

Interventions

  • DeviceApollo Wearable

    Participants will be provided with the Apollo wearable device and asked to install the study mobile application on their mobile phones. Participants will use the Apollo for at least 30 minutes after waking up and at least 30 minutes before bed on the corresponding settings for those times of the day. They will be given the Apollo Device TVS (10-200 Hz) to borrow, which they will be instructed to wear daily. They will be asked to wear the device until all study data is collected.

    Also known as: Apollo Neuro

06

What researchers measure

Primary outcomes

  1. Copenhagen Burnout Inventory

    The Copenhagen Burnout Inventory (CBI) is a 19-item self reported measure of burnout. It contains three sub-scales measuring personal burnout, work-related burnout, and client-related burnout

    Time frame: Through study completion, on average 8 weeks

  2. Perceived Stress Scale (PSS-10)

    The Perceived Stress Scale (PSS) is the most widely used psychological instrument for measuring the perception of stress using a 10-item survey. It is a measure of the degree to which situations in one's life are appraised as stressful.

    Time frame: Through study completion, on average 8 weeks

Secondary outcomes

  1. The Quick Inventory of Depressive Symptomatology

    The QIDS is a brief, 16-item self-rated assessment tool used to evaluate the symptoms of depression present in a patient during the past week.

    Time frame: Through study completion, on average 8 weeks

  2. Pittsburgh Sleep Quality Index (PSQI)

    The Pittsburgh Sleep Quality Index (PSQI) is a self-rated questionnaire which assesses sleep quality and disturbances over a 1-month time interval. With a range of scores 1-21.

    Time frame: Through study completion, on average 8 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Nov 2027, 46 months after the start.

Of 128 non-industry interventional studies with no phase under Burnout, Professional, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 22. This study's planned 46 months is above that.

Counting every sponsor, half of 132 studies reached it within 11 months; a quarter within 6 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 9, 2023
First posted
Feb 16, 2023
StartActual
Jan 15, 2024
Primary completionEst.
Nov 2027
CompletionEst.
Nov 2027
Last update
Feb 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05731856
Lead sponsor
Michelle Thompson
Collaborators
The Board of Medicine, Apollo Neuroscience, Inc.
Responsible party
Michelle Thompson (Faculty in Department of Family Medicine, University of Pittsburgh) — Sponsor-investigator
First posted
Feb 16, 2023
Start date
Jan 15, 2024
Primary completion
Nov 2027 (estimated)
Completion
Nov 2027 (estimated)
Last update
Feb 18, 2026

Study contacts

Franchesca Inay, BS
Contact
inay.franchesca@medstudent.pitt.edu
5512234990
Mahi Mandala, PhD
Contact
mahi@apolloneuro.com
4129450345
Michelle Thompson, DO
principal investigator · University of Pittsburgh

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion